We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GlaxoSmithKline plc (GSK - Free Report) , one of the largest health care companies, reshaped its business following the Mar 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses.
This UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products).
However, like many of its peers, Glaxo is facing challenges in the form of increasing competition, genericization and pricing pressure in major markets.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.
Glaxo’s performance has been pretty good so far, with the company’s earnings beating expectations thrice in the four trailing quarters. Overall, the company has delivered an average positive surprise of 8.96%.
Currently, Glaxo has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Glaxo reported core earnings of 48 cents per American depositary share, missing our consensus estimate of 57 cents.
Revenues: Revenues were up 6% year over year at constant exchange rate (CER).
Key Stats: Sales in the quarter were driven by strong performance across all three business segments. The Consumer Healthcare and Vaccines segments were up 9% and 14%, respectively. The Pharmaceuticals segment was also up 3% at CER.
2017 Guidance: Glaxo expects core 2017 earnings growth of 5-7% at CER. This is based on an expected decline in 2017 US Advair sales of 15-20%.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on GSK earnings report later!
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y
GlaxoSmithKline plc (GSK - Free Report) , one of the largest health care companies, reshaped its business following the Mar 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses.
This UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products).
However, like many of its peers, Glaxo is facing challenges in the form of increasing competition, genericization and pricing pressure in major markets.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.
Glaxo’s performance has been pretty good so far, with the company’s earnings beating expectations thrice in the four trailing quarters. Overall, the company has delivered an average positive surprise of 8.96%.
Currently, Glaxo has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Glaxo reported core earnings of 48 cents per American depositary share, missing our consensus estimate of 57 cents.
Revenues: Revenues were up 6% year over year at constant exchange rate (CER).
Key Stats: Sales in the quarter were driven by strong performance across all three business segments. The Consumer Healthcare and Vaccines segments were up 9% and 14%, respectively. The Pharmaceuticals segment was also up 3% at CER.
2017 Guidance: Glaxo expects core 2017 earnings growth of 5-7% at CER. This is based on an expected decline in 2017 US Advair sales of 15-20%.
Share Price Impact: In-active in pre-market trading.
Check back later for our full write up on GSK earnings report later!
GlaxoSmithKline PLC Price and EPS Surprise
GlaxoSmithKline PLC Price and EPS Surprise | GlaxoSmithKline PLC Quote
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>